<SEC-DOCUMENT>0001564590-20-036408.txt : 20200805
<SEC-HEADER>0001564590-20-036408.hdr.sgml : 20200805
<ACCEPTANCE-DATETIME>20200805064110
ACCESSION NUMBER:		0001564590-20-036408
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20200805
FILED AS OF DATE:		20200805
DATE AS OF CHANGE:		20200805

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioNTech SE
		CENTRAL INDEX KEY:			0001776985
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			2M
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39081
		FILM NUMBER:		201075539

	BUSINESS ADDRESS:	
		STREET 1:		AN DER GOLDGRUBE 12
		CITY:			MAINZ
		STATE:			2M
		ZIP:			55131
		BUSINESS PHONE:		0049613190847081

	MAIL ADDRESS:	
		STREET 1:		AN DER GOLDGRUBE 12
		CITY:			MAINZ
		STATE:			2M
		ZIP:			55131
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>bntx-6k_20200805.htm
<DESCRIPTION>6-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
bntx-6k_20200805.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-top:3pt;text-align:center;margin-bottom:0pt;margin-left:7.91%;margin-right:7.78%;text-indent:0%;font-weight:bold;font-size:20pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.91%;margin-right:7.78%;text-indent:0%;font-weight:bold;font-size:20pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.91%;margin-right:7.78%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:13pt;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:7.91%;margin-right:7.78%;text-indent:0%;font-weight:bold;font-size:20pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 6-K</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="text-align:center;margin-top:5pt;margin-bottom:0pt;margin-left:7.91%;margin-right:7.78%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a&#8209;16 OR 15d&#8209;16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.91%;margin-right:7.78%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">FOR THE MONTH OF AUGUST<font style="letter-spacing:-0.05pt;"> </font>2020</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="text-align:center;margin-top:5pt;margin-bottom:0pt;margin-left:7.91%;margin-right:7.78%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">COMMISSION FILE NUMBER 001-39081</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.91%;margin-right:7.78%;text-indent:0%;font-weight:bold;font-size:20pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BioNTech SE</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.91%;margin-right:7.78%;text-indent:0%;color:#333333;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Translation of registrant&#8217;s name into English)</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:40.27%;margin-right:40.08%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">An der Goldgrube 12 D-55131 Mainz Germany</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.91%;margin-right:7.78%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">+49 6131-9084-0</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.91%;margin-right:7.78%;text-indent:0%;color:#333333;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="margin-top:5pt;margin-bottom:0pt;margin-left:0.97%;margin-right:2.14%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20&#8209;F or Form 40&#8209;F: Form 20&#8209;F <font style="font-family:Segoe UI Symbol;">&#9746; </font>Form 40&#8209;F <font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0.97%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is submitting the Form 6&#8209;K in paper as permitted by Regulation S&#8209;T Rule 101(b)(1): <font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0.97%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is submitting the Form 6&#8209;K in paper as permitted by Regulation S&#8209;T Rule 101(b)(7): <font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:7.91%;margin-right:7.78%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:13pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:7pt;margin-bottom:0pt;margin-left:0.97%;margin-right:0.78%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 5, 2020, BioNTech SE (the &#8220;Company&#8221;) issued a press release, announcing that the Company and Fosun Pharma dosed the first 72 participants with BNT162b1 following IND approval by the Chinese regulatory authority, National Medical Products Administration (NMPA). The press release is attached hereto<font style="letter-spacing:-1pt;"> </font>as Exhibit<font style="letter-spacing:-0.7pt;"> </font>99.1. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:7.91%;margin-right:7.78%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURE</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.97%;margin-right:5.84%;text-indent:7%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50.75%;"></td>
<td style="width:6.43%;"></td>
<td style="width:42.82%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:7.78%;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:7.78%;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BioNTech SE</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:8.5pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:8.5pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:8.5pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.78%;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.78%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.78%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">/s/ Dr.</font><font style="text-decoration:underline;letter-spacing:-0.05pt;"> </font><font style="text-decoration:underline;">Sierk Poetting</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.78%;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.78%;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:0.78%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Dr. Sierk<font style="letter-spacing:-0.1pt;"> </font>Poetting</p></td>
</tr>
<tr>
<td valign="top" >
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:13pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:13pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:13pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:14.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: August 5, 2020</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;margin-left:7.91%;margin-right:7.78%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT INDEX</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:8.5pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:5.06%;width:94.94%;">
<tr>
<td style="width:14.67%;"></td>
<td style="width:80.27%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Exhibit</font></p></td>
<td valign="top" >
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Description of</font><font style="text-decoration:underline;letter-spacing:-0.05pt;"> </font><font style="text-decoration:underline;">Exhibit</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-top:4pt;margin-bottom:0pt;margin-left:0pt;;margin-right:4.86%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="top" >
<p style="text-align:justify;margin-top:4pt;margin-bottom:0pt;margin-left:0pt;;margin-right:4.86%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Press<font style="letter-spacing:-0.5pt;"> </font>Release<font style="letter-spacing:-0.45pt;"> </font>dated<font style="letter-spacing:-0.45pt;"> </font>August 5,<font style="letter-spacing:-0.45pt;"> </font>2020 -<font style="letter-spacing:-0.5pt;"> </font>BioNTech and Fosun Pharma Announce Start of Clinical Trial of mRNA-based COVID-19 Vaccine Candidate in China.</p></td>
</tr>
</table></div>
<p style="text-align:right;margin-top:4pt;margin-bottom:0pt;margin-right:5.45%;text-indent:0%;font-size:9.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>bntx-ex991_7.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
bntx-ex991_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:49.94%;"></td>
<td style="width:49.94%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:24pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><img src="g51vl1kl5zxx000001.jpg" title="" alt="" style="width:231px;height:25px;"></p></td>
<td valign="top" >
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g51vl1kl5zxx000002.jpg" title="" alt="" style="width:210px;height:49px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:14pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">BioNTech and Fosun Pharma Announce Start of <br />Clinical Trial of mRNA-based COVID-19 Vaccine Candidate in China</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:16pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.94%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.94%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-style:italic;font-family:Arial;">Phase 1 study will evaluate safety and immunogenicity in Chinese participants to support potential regulatory approval pathway in China</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.94%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.94%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-style:italic;font-family:Arial;">Total of 144 participants to be enrolled in two age groups (18-55 and &gt;55 years)</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.94%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.94%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-style:italic;font-family:Arial;">Trial participants to receive either 10&#181;g or 30&#181;g of BNT162 or a placebo </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.94%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.94%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-style:italic;font-family:Arial;">Clinical supply from BioNTech&#8217;s GMP-certified mRNA production facilities in Europe </font></p></td></tr></table></div>
<p style="text-align:justify;margin-top:0pt;margin-bottom:8pt;margin-left:7.94%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">MAINZ, Germany, <font style="color:#000000;">and SHANGHAI, China</font>, August 5, 2020 (GLOBE NEWSWIRE) <font style="font-weight:normal;">&#8211;</font><font style="font-family:Calibri;font-weight:normal;"> </font><font style="text-decoration:underline;font-weight:normal;">BioNTech SE</font><font style="font-weight:normal;"> (Nasdaq: BNTX, &#8220;BioNTech&#8221; or &#8220;the Company&#8221;) and </font><font style="text-decoration:underline;font-weight:normal;">Shanghai Fosun Pharmaceutical (Group) Co., Ltd</font><font style="font-weight:normal;"> (&#8220;Fosun Pharma&#8221; or &#8220;Group&#8221;; Stock Symbol: 600196.SH, 02196.HK), today announced that the first 72 participants have already been dosed with BNT162b1 following IND approval by the Chinese regulatory authority, National Medical Products Administration (NMPA). BioNTech and Fosun Pharma are jointly developing the COVID-19 vaccine candidate in China. The trial is part of BioNTech&#8217;s global development program aimed at supporting a global supply upon regulatory approval. </font></p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The randomized, placebo-controlled, observer-blinded Phase 1 clinical trial in China will enroll 144 healthy subjects to evaluate the safety and immunogenicity of the vaccine as well as to confirm dose selection. The first group of subjects immunized in Stage 1 of the study will be healthy adults aged 18 to 55 years, followed by elderly healthy participants (&gt;55 years). As part of the two-dose cohort design, subjects will receive two injections (prime-boost), 21 days apart, of 10&#181;g or 30&#181;g of the vaccine candidate or placebo. The dose range selection was determined based on early data from clinical trials conducted in Germany and the United States. The participants will be dosed in Taizhou Clinical Phase1 Center, Jiangsu province.</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="OLE_LINK1"></a><a name="OLE_LINK1"></a>The study is designed to support the regulatory approval process for the Chinese market and intends to confirm that the safety and immunogenicity profile observed in participants from the German and US trials is comparable to that of Chinese participants. The ongoing clinical studies conducted in Germany and the United States will continue to support studies in China. </p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="Background-color:#FFFFFF;">We are proud to be among the first international biopharmaceutical companies to initiate a clinical trial of a COVID-19 vaccine candidate in China as part of our effort to make our vaccine available globally, if approved. This is an important step toward our goal to reach marketing authorization and ensure vaccine supply in China to help prevent new COVID-19 outbreaks in the most populous country in world&#8221;, said </font><font style="font-weight:bold;Background-color:#FFFFFF;">CEO and Co-founder of BioNTech, Ugur Sahin.</font></p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Ai-Min Hui, President of Global R&amp;D, and Chief Medical Officer of Fosun Pharma</font><font style="Background-color:#FFFFFF;font-weight:normal;"> said: &#8221;Dosing the first Chinese subject with BNT162b1 marks a milestone of the global co-development program in China. We are closely working with BioNTech and regulatory authorities to evaluate the safety and efficacy of the vaccine candidate, in order to synchronize the development process in China with other countries, and to bring the vaccine to public as soon as possible, if the vaccine succeeds.&#8221;</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following on from the ongoing Phase 1/2 studies in Germany and the United States, the Chinese study will initially evaluate nucleoside-modified messenger RNA (modRNA) candidate </font><font style="font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BNT162b1, one of two vaccine candidates based on BioNTech&#8217;s proprietary mRNA technology to have received FDA Fast Track designation</font><font style="font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in the United States</font><font style="font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Me</font><font style="font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">anwhile, BNT162b2, the other </font><font style="font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">vaccine candidate is currently being evaluated in a global Phase 2b/3 trial conducted by BioNTech and Pfizer which commenced on July 27</font><font style="font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup></font><font style="font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The companies also intend to explore the </font><font style="font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">possibility</font><font style="font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of initiating clinical development of other vaccine candidates based on BioNTech&#8217;s proprietary mRNA technology in China.</font><font style="font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">During the clinical development stage, BioNTech will provide the clinical supply of the vaccine from its GMP-certified mRNA manufacturing facilities in Europe. If the vaccine receives marketing authorization in China, Fosun Pharma will </font>exclusively <font style="Background-color:#FFFFFF;">commercialize the vaccine in </font>Mainland China, Hong Kong and Macau Special Administration Regions and in Taiwan<font style="Background-color:#FFFFFF;">. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">About BioNTech </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Genevant, Fosun Pharma, and Pfizer. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For more information, please visit <font style="text-decoration:underline;">www.BioNTech.de</font>. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">About Fosun Pharma</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (&#8220;Fosun Pharma&#8221;; stock code: 600196.SH, 02196.HK) is a leading healthcare group in China. Fosun Pharma has built a strong root in China and developed a global operation strategy, with pharmaceutical manufacturing and R&amp;D being the largest and core business segment, together with strong presences in medical devices and diagnostics, healthcare services, pharmaceutical distribution and retail.</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With R&amp;D innovation as core driving factor, Fosun Pharma continues to optimize its pharmaceutical operations across both innovative and generic drugs. The company has established international R&amp;D centers for excellence in areas such as innovative small molecule drugs, high-value generic drugs, biologics, and cell therapy.</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under guidance of our 4IN strategy (Innovation, Internationalization, Integration and Intelligentization), Fosun Pharma follows the brand concept of Innovation for Good Health and strives to be a leading enterprise in the global pharmaceutical and healthcare markets.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For more information, please visit: <font style="text-decoration:underline;">www.fosunpharma.com</font>. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-weight:bold;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">BioNTech&#8217;s Forward-Looking S</font><font style="font-weight:bold;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">tatements</font></p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This press release contains &#8220;forward-looking statements&#8221; of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, BioNTech&#8217;s efforts to combat COVID-19; the timing to initiate clinical trials of BNT162 and anticipated publication of data from these clinical trials; the collaboration between BioNTech and Fosun Pharma, to develop a potential COVID-19 vaccine; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and, if approved, market demand. Any forward-looking statements in this press release are based on BioNTech management&#8217;s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: competition to create a vaccine for COVID-19. For a discussion of these and other risks and uncertainties, see BioNTech&#8217;s Annual Report on Form 20-F filed with the SEC on March 31, 2020, which is available on the SEC&#8217;s website at <font style="text-decoration:underline;">www.sec.gov</font>. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">BioNTech Contacts</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Media Relations</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jasmina Alatovic</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+49 (0)6131 9084 1513 or +49 (0)151 1978 1385</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">Media@biontech.de</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Investor Relations</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sylke Maas, Ph.D.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+49 (0)6131 9084 1074</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investors@biontech.de</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Fosun Pharma Media Contact</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Barney Liu</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+86 (21) 3396 7123</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-family:Arial;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">liumingyi@fosunpharma.com</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;margin-left:7.94%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g51vl1kl5zxx000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g51vl1kl5zxx000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !4 6@# 2(  A$! Q$!_\0
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M@O\ Z,>M31_ \/C#X/Z:T(5-4MC.;>0\;OWK91O8_H?QK+^.?_(WV'_7@O\
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M\*=1F\-_$&XT6\.P7)>UD4]!*A.W^3#_ (%17'BZ?)5=MGJ=6&GS4U?H=?\
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M&;_PB'AG_H7=(_\  */_ .)H_P"$0\,_]"[I'_@%'_\ $T457M)]Q<D>P?\
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(0 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g51vl1kl5zxx000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g51vl1kl5zxx000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $M"JD# 2(  A$! Q$!_\0
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MT:/M$W_/:3_OHU'10%V2?:)O^>TG_?1H^T3?\]I/^^C4=% 79)]HF_Y[2?\
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MYC?.W4]Z]$KSF3_6-]37S^>MI4_G^A40\Q_[[?G1YC_WV_.FT5\[=E#O,?\
MOM^='F/_ 'V_.FT478#O,?\ OM^='F/_ 'V_.FT478#O,?\ OM^='F/_ 'V_
M.FT478#O,?\ OM^='F/_ 'V_.FT478#O,?\ OM^='F/_ 'V_.FT478#O,?\
MOM^='F/_ 'V_.FT478#O,?\ OM^='F/_ 'V_.FT478#O,?\ OM^='F/_ 'V_
M.FT478#O,?\ OM^='F/_ 'V_.FT478#O,?\ OM^='F/_ 'V_.FT478#O,?\
MOM^='F/_ 'V_.FT478#O,?\ OM^='F/_ 'V_.FT478#O,?\ OM^='F/_ 'V_
M.FT478#O,?\ OM^='F/_ 'V_.FT478#O,?\ OM^='F/_ 'V_.FT478#O,?\
MOM^='F/_ 'V_.FT478#O,?\ OM^='F/_ 'V_.FT478#O,?\ OM^='F/_ 'V_
M.FT478#O,?\ OM^='F/_ 'V_.FT478#O,?\ OM^='F/_ 'V_.FT478#O,?\
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MT:/M$W_/:3_OHU'10%V2?:)O^>TG_?1H^T3?\]I/^^C4=% 79)]HF_Y[2?\
M?1H^T3?\]I/^^C4=% 79)]HF_P">TG_?1H^T3?\ /:3_ +Z-1T4!=DGVB;_G
MM)_WT:/M$W_/:3_OHU'10%V2?:)O^>TG_?1H^T3?\]I/^^C4=% 79)]HF_Y[
M2?\ ?1H^T3?\]I/^^C4=% 79)]HF_P">TG_?1H^T3?\ /:3_ +Z-1T4!=DGV
MB;_GM)_WT:/M$W_/:3_OHU'10%V2?:)O^>TG_?1H^T3?\]I/^^C4=% 79] 6
M'.G6I/\ SQ3^0JQ5;3_^0;:_]<4_D*LU1])'9!1110,**** "BBB@ HHHH *
M*** "BBB@ HHHH **CFGAMHFEGE2*->KNP 'XFN5U/XAZ19;DM1)>R#^Y\J?
M]]'^@-!$ZL(+WG8ZZFNZQH7=@JCJ6. *\FU#XAZU=Y6W,5HA_P">:Y;\S_0"
MN:NK^\OGWW=U-.WK(Y;'YTKG'/'P7PJY[-=^+=!LB1+J4+,.T69/_0<UB7/Q
M+TN/BWM;J8^K (/YD_I7EE%%SFECZKVT.\G^)]VV?L^FP1^GF2%_Y8K-F^(>
MORYV200_[D0/_H6:Y6B@Q>)K/>1N2^,?$$WWM3E'^XJK_(54?Q!K,F=^JWI!
MZCSV _G6=12,W4F]VRTVIW[G+WURV/65C_6HVNKASE[B5CZER:AHH)YF2?:)
MO^>TG_?1H^T3?\]I/^^C4=% KLD^T3?\]I/^^C1]HF_Y[2?]]&HZ* NR3[1-
M_P ]I/\ OHT?:)O^>TG_ 'T:CHH"[)/M$W_/:3_OHT?:)O\ GM)_WT:CHH"[
M)/M$W_/:3_OHT?:)O^>TG_?1J.B@+LD^T3?\]I/^^C1]HF_Y[2?]]&HZ* NR
M3[1-_P ]I/\ OHT?:)O^>TG_ 'T:CHH"[)/M$W_/:3_OHT?:)O\ GM)_WT:C
MHH"[)/M$W_/:3_OHT?:)O^>TG_?1J.B@+LD^T3?\]I/^^C1]HF_Y[2?]]&HZ
M* NR3[1-_P ]I/\ OHT?:)O^>TG_ 'T:CHH"[)/M$W_/:3_OHUWWPQD=[G4M
M[LV$CQDY[M7GM>@?"[_CYU+_ '(_YM3.G"/]]$](HHHIGN!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7CGCB:5?&-^JR. /+X#'_
M )YK7L=>,^.O^1RO_P#MG_Z+6DSAQ_\ "7K_ )F#]HF_Y[2?]]&C[1-_SVD_
M[Z-1T4CR+LD^T3?\]I/^^C1]HF_Y[2?]]&HZ* NR3[1-_P ]I/\ OHU['N;U
M/YUXQ7LU,[L&_B^1X[<?\?,O^^?YU'4EQ_Q\R_[Y_G4=(X7N%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7<^%/',EFR6.K2-);=$G/+1^Q]1^HK
MAJ*#2G5E3ES1/H=65T5T8,K#(8'((I:\T\!^*FAE31[Z3,3G%N['[I_N_0]J
M]+JCW*-6-6/,@HHHH-0HHHH **** "N$^)__ "#;#_KLW\J[NN$^)_\ R#;#
M_KLW\J&<^+_@R/,J***D\(**** "O7?AY_R*D?\ UV?^=>15Z[\//^14C_Z[
M/_.FCMP'\7Y'5T444SV HHHH **** "BBB@ HHHH **** "FNZ11M)(RHBC+
M,QP />L?7_$UAX?A_?MYEPPRD"'YC[GT'O7E6N>)M1UZ4_:)=EN#\L"'"CZ^
MI]S0<U?%0I:;L[K6OB)8V9:'34^US#CS#Q&/ZM^'YUY_JOB#5-98_;;MV3.1
M$ORH/P']>:S**1Y57$5*F[T"BBBD8!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %.1WC=71F5E.0RG!%-HH ZW1_B!JFGE8
M[P_;8!Q\YPX^C=_QS7HFC>)=,UQ/]$GQ-C)@D^5Q^'?ZC->'4Y'>*19(V9'4
MY5E."#3N==+&5(:/5'T-17FGAWXA2P;+;6<RQ]!<J/F7_>'?Z]?K7H\$\5S
MD\$BR1.,JZG((IGJTJT*JO$DHHHH-0HHHH **** "BBB@ HHHH **** .2\4
M?\A./_KB/YM6)6WXH_Y"<?\ UQ'\VK$KXG,?]ZGZFBV"BBBN( HHHH ****
M)[6[FLIUFA;:PZCL1Z&NSTW5(=1ARORRJ/G0]OI[5PM20S26\JRQ.4=3D$5Z
M&!Q\\+*V\>W^0FKGHE%9FDZQ'J";'PEP!RO][W%:=?7T:T*T%.#NB HHHK0
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ KSF3_6-]37HU><R?ZQOJ:^?S[:G\_P!"HC:***^<*"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\9\=?\
M(Y7_ /VS_P#1:U[-7C/CK_D<K_\ [9_^BUI,X<P_A+U_S.=HHHI'D!1110 5
M[-7C->S4SMP?VOD>.W'_ !\R_P"^?YU'76R_#[7GF=A'!@L2/WHIO_"O-?\
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M_D&V'_79OY4,Y\7_  9'F5%%%2>$%%%% !7KOP\_Y%2/_KL_\Z\BKUWX>?\
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M<UC-Y4P ;&[@YXJO7-*,H2Y9*S0!1114@%%%% !16JGAZ_=%8+'AAD?/3O\
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M^%>:_P#\\[?_ +^B@/J]7^5G*45U?_"O-?\ ^>=O_P!_11_PKS7_ /GG;_\
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M** "O9J\9KV:F=N#^U\CHJ***9[ 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(RJZE7
M4,I&"",@TM% '(:[X!T_45>6P"V=T>0%'[MOJ.WX?D:\PU#3[K2[Q[2\B,<R
M=0>A'J#W%>_5A>*/#L.OZ:R!56[C!,$GH?[I]C_]>E8X<1A(S7-#1GBE%.DC
M>*1HY%*NA*LIZ@CJ*;2/("BBB@ IT;M%(LB,5="&4CL13:* /?\ 3KM;_3;:
M[7I-$KX],CI5FN9\!7)N/"5LI.3"SQG\\C]"*Z:J/HJ<N:"EW"BBB@L****
M"N$^)_\ R#;#_KLW\J[NN$^)_P#R#;#_ *[-_*AG/B_X,CS*BBBI/""BBB@
MKUWX>?\ (J1_]=G_ )UY%7KOP\_Y%2/_ *[/_.FCMP'\7Y'5T444SV HHHH
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MV?$W_(5'_7(?S-8U?$8__>I^IHM@HHHKC **** /0[?_ (]HO]P?RJ6HK?\
MX]HO]P?RJ6OT&'PHS"BBBJ **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBJ&M:K#HNE37TW.P81?[S'H*!-J*NSF_'?B<Z9;?V;9OB[F7]X
MP/,:?XG_ #VKRJI[R[FO[R6[N'WS2L68_P">U04CP:]9U9WZ!1112,0HHHH
M**** "BM?1O#>IZZ_P#HD&(<X::3A!^/?\*]#TCX?:78!9+W-[,.3OX0?\![
M_C3-Z6&J5=4M#S&QTJ_U.3996DLY[E%X'U/05U-A\-=2G :]N8;5?[H_>-^G
M'ZUZA%%'#&L<4:QHHP%08 _"GT6/0A@(+XG<Y"S^'.BP &X:XNF[AGVK^2\_
MK6Y;>'=&L\>1IEJI'1C&&/YGFM.BF=,:-..R$5510JJ%4= !BEHHH-0HHHH
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MT3'YT/?Z>]=G:7<-[ LT+;E/4=P?0U]=@<?#%1MM+M_D0U8GHHHKT!!1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "O&?'7_(Y7__ &S_ /1:U[-7C/CK_D<K_P#[9_\
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M]:]6J"RLX=/LH;2W3;#$H51_GO4]4>]0HJE"W4****#8**** "BBB@ HHHH
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MS(:L7Z***]404444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ***9[ 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9O<5J5YPCLCAT8JRG((/(KK='UQ;L+;W)"S] W9__KU]/EV:*K:E6^+H^_\
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MZ7/49Z#\!C\<UT-%%4?10@H145T"BBB@H**** "BBB@ HHHH **** "BBB@
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M^T0_\]H_^^A0%T245']HA_Y[1_\ ?0H^T0_\]H_^^A0%T244=1D44#"BBB@
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M'_GM'_WT* NB2BH_M$/_ #VC_P"^A1]HA_Y[1_\ ?0H"Z)**C^T0_P#/:/\
M[Z%'VB'_ )[1_P#?0H"Z)**C^T0_\]H_^^A1]HA_Y[1_]]"@+HDHJ/[1#_SV
MC_[Z%'VB'_GM'_WT* NB2O&?'7_(Y7__ &S_ /1:U[,"",@Y!KQGQU_R.5__
M -L__1:TF<68?PEZ_P"9SM%%%(\@**** "O9J\9KV:F=N#^U\CQVX_X^9?\
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MX0T]<8RC-^;$_P!:WJH^@H*U**\@HHHH-0HHHH **** "BBB@ HHHH ****
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MM(8^?D15YZ\"FCT<O7O29+1113/4"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** .4^(?_(J2?\ 79/YUY%7KOQ#_P"14D_Z[)_.O(J3
M/&Q_\7Y!1112.,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M KV:O&:]FIG;@_M?(\=N/^/F7_?/\ZCJ2X_X^9?]\_SJ.D<3W"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** .@TKPE=:M%')%?6$8D&0KSY<?\  1GFNPTW
MX:V,!#ZA<R73#^!!L7\>Y_,5Y?6OIOB?6-*(%M>R>6/^64AWI^1Z?A3.FC4H
MQ?OQ_KT/:K2RM;" 06D$<,8_A1<"IZXG1/B+9WC+#J<8M)3P) <QD_S7]1[U
MVB.LB*Z,&1AE64Y!%,]BE4A->XQU%%%!H%%%% !1110 4444 %<)\3_^0;8?
M]=F_E7=UPGQ/_P"0;8?]=F_E0SGQ?\&1YE1114GA!1110 5Z[\//^14C_P"N
MS_SKR*O7?AY_R*D?_79_YTT=N _B_(ZNBBBF>P%%%% !1110!Y5\3/\ D9+?
M_KT7_P!#>N,KL_B9_P C);_]>B_^AO7&4CP<3_&D%%%%(P"BBB@#W'PJNSPM
MIHSG]PI_/FM>L?PHQ;PKII/_ #Q _*MBJ/HJ7P+T"BBB@L**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M KS'XG*!JMBW<P$?DW_UZ].KS'XG,#JMBG<0$_FW_P!:AG)C?X+.%HHHJ3Q0
MHHHH *]J\%_\BAI_^XW_ *$:\5KVKP7_ ,BAI_\ N-_Z$::.[+_XC]#>HHHI
MGKA1110 4444 <EXH_Y"<?\ UQ'\VK$K;\4?\A./_KB/YM6)7Q.8_P"]3]31
M;!1117$ 4444 >@V7_'C;_\ 7)?Y5/4%E_QXV_\ UR7^53U^@4_@7H9A1115
M@%%%% !1110 4444 %5KVQAOX#%,O^ZPZJ:LT5,X1G%QDKI@<%?Z?-I\_ERC
M*G[KCHU5*]"N;6&[@:&9 RG\Q[BN-U/2I=.EY^>%C\K_ -#[U\IF&6RP[YX:
MQ_(M.YGT445Y(PHHHH **** +NFZG-ITVY/FC;[\9/!_^O7:6EW#>P":!LJ>
MH[@^AKSZK-E?36$XEA;_ 'E/1A7JY?F4L.^2>L?R]!-7._HJI8:A#J$'F1'#
M#[R'JM6Z^LA.-2*E%W3("BBBJ **** "BBB@ HHHH *\YD_UC?4UZ-7G,G^L
M;ZFOG\^VI_/]"HC:***^<*"BBB@#0T3_ )#-M_O'^1KN*X?1/^0S;?[Q_D:[
MBOJ<C_@2]?T1,@HHHKVB0HHHH **** "BBB@ HHHH **** .0\3?\A4?]<A_
M,UC5L^)O^0J/^N0_F:QJ^(Q_^]3]31;!1117& 4444 >AV__ ![1?[@_E4M1
M6_\ Q[1?[@_E4M?H,/A1F%%%%4 4444 %%%% !1110 4444 %<A\1_\ D6%_
MZ^4_DU=?7(?$?_D6%_Z^4_DU!CB?X4O0\FHHHJ3P HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#W_3_P#D&VO_ %Q3^0JS5;3_ /D&
MVO\ UQ3^0JS5'TD=D%%%% PHHHH *\2\7,6\6:B2<_O<?D!7MM>)>+U*^+-1
M!_YZY_,"DS@S#^&O4Q****1Y(4444 %?1%?.]?1%-'I9=]KY?J%%%%,],***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y3XA_\ (J2?
M]=D_G7D5>N_$/_D5)/\ KLG\Z\BI,\;'_P 7Y!1112.,**** "BBB@ HHHH
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M>?\ (J1_]=G_ )TT=N _B_(ZNBBBF>P%%%% !1110!Y?\3@?[:LVQP;?&?\
M@1KAZ[_XH1XN]-DY^9'7\B/\:X"DSPL6K5I!1112.<**** /:?!,GF^$-/.<
MX5EZ^CL*WZY'X<S^;X8,>>8IW7'UP?ZUUU4?04'>E%^04444&H4444 %%%%
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M ,_-A_W\?_XBC_A6>L_\_-A_W\?_ .(H#ZM6_E.,HKL_^%9ZS_S\V'_?Q_\
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M;^4XRBNS_P"%9ZS_ ,_-A_W\?_XBC_A6>L_\_-A_W\?_ .(H#ZM6_E/3-/\
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M7J_RLY"BNO\ ^%<:Y_?M/^_I_P */^%<:Y_?M/\ OZ?\* ^KU?Y6<A177_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P!<1_-JQ*^)S'_>I^IHM@HHHKB **** /0;+_CQM_\ KDO\JGJ"R_X\;?\
MZY+_ "J>OT"G\"]#,****L HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MR-7T5+X&:'"7 _)_K[^]<A)&\4C1R*5=3@@CD5Z-6;JND1:C'N&$G4?*_K['
MVKQ<QRM5KU*6DNW?_@E)G$T5+<6\MK,T,R%77J#45?+M.+L]R@HHHI %%%%
M!6_HVNF';;7;$Q=$D/\ #]?:L"BM\/B*F'GSP8-7/1P0P!!!!&01WI:X_2-;
M>R(AG)>W/3U3Z>WM771R)+&KQL&1AD$=#7V&#QM/%0O'?JB&K#J***[!!7G,
MG^L;ZFO1J\YD_P!8WU-?/Y]M3^?Z%1&T445\X4%%%% &AHG_ "&;;_>/\C7<
M5P^B?\AFV_WC_(UW%?4Y'_ EZ_HB9!1117M$A1110 4444 %%%% !1110 44
M44 <AXF_Y"H_ZY#^9K&K9\3?\A4?]<A_,UC5\1C_ />I^IHM@HHHKC ****
M/0[?_CVB_P!P?RJ6HK?_ (]HO]P?RJ6OT&'PHS"BBBJ **** "BBB@ HHHH
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MZH^AIS4XJ2ZA11106%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!RGQ#_P"14D_Z[)_.O(J]=^(?_(J2?]=D_G7D5)GC8_\ B_(****1QA11
M10!ZC\,O^0)>?]?/_LHKMZXCX9?\@2\_Z^?_ &45V]4>[A?X,0HHHH.@****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWC_(UW%</HG_ "&;;_>/\C7<5]3D?\"7K^B)D%%%%>T2%%%% !1110 4444
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M% !1110 4444 %%%% !1110 4444 %%%% !113)IHK>)I9I$CC499W; 'XT
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH QO%6D_VSX?N+9%S,H\R'_>'
M;\1D?C7B%?1%>/>.-$.DZXTT:8MKLF1,= W\0_/G\:3/-Q]*Z51',4444CS
MHHHH **** .[\'^-OL:QZ;JLA, ^6*<\^7[-[>_;Z=/3%97171@RL,A@<@BO
MGBNB\/>,+_02(L_:+//,+G[O^Z>W\J=SOPV,Y?=J;'LU%9.C>(],UR,&TG'F
MXRT+\./P[_49K6IGJQDI*Z"BBB@84444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!RGQ#_P"14D_Z[)_.O(J]=^(?_(J2?]=D_G7D5)GC8_\ B_(****1QA11
M10!ZC\,O^0)>?]?/_LHKMZXCX9?\@2\_Z^?_ &45V]4>[A?X,0HHHH.@****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX]S1HK._M_1O^@O8?^!*?XT?V_HW_07L/_ E/\: YX]S1HK._M_1O^@O8?\
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MZ>_XTF<F+H>TC=;H\;HISH\4C1R*5=2596&"".QIM(\4**** "BBB@ HHHH
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MTR'1]+@L8/NQKRV.6;N3]331VX*CSSYWLB[1113/8"BBB@ HHHH *X3XG_\
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L+6-#%SNN+4
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M4 %%%% 'O^G_ /(-M?\ KBG\A5FJVG_\@VU_ZXI_(59JCZ2.R"BBB@84444
M%%%% !1110 5YEXU\'&U>35--BS;GF:%!_JS_> _N_R^G3TVB@RK48U8\K/G
M>BO1_%7@/S"]]HR ,?FDMAW]T_P_+TKSIT:-V1U*LIPRL,$&I/$JT94I6D-H
MHHH,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "O0/A=_Q\ZE_N1_S:O/Z] ^%W
M_'SJ7^Y'_-J9T83^-$](HHHIGNA1110 4444 <I\0_\ D5)/^NR?SKR*O7?B
M'_R*DG_79/YUY%29XV/_ (OR"BBBD<84444 >H_#+_D"7G_7S_[**[>N(^&7
M_($O/^OG_P!E%=O5'NX7^#$****#H"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\9\=?\ (Y7_ /VS
M_P#1:U[-7C/CK_D<K_\ [9_^BUI,X<P_A+U_S.=HHHI'D!1110 5[-7C->S4
MSMP?VOD>.W'_ !\R_P"^?YU'4EQ_Q\R_[Y_G4=(XGN%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !4D$,MS.D,,;22N=JHHR2:N:3HM_K=SY-E 7Q
M]YSPB?4UZOX;\)V?A^+S.)[UAAYB.GLH[#]33.BAAI57Y$?A'PLF@6AEGVO?
MS#YV'.P?W1_4_P"%=+113/:A",(\L0HHHH+"BBB@ HHHH *X3XG_ /(-L/\
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MY5/7Z!3^!>AF%%%%6 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZM5['&45V?\ P@7_ %$__('_ -E1_P (%_U$_P#R!_\ 94!]6J]CC**[/_A
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M_A O^HG_ .0/_LJ ^K5>QQE%=HO@#<P']I]3C_4?_95J1_"Z$?ZW57;_ '8
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M_"!?]1/_ ,@?_94?\(%_U$__ "!_]E0'U:KV.,KUWX>?\BI'_P!=G_G7*_\
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ME^TN/XK@[OTZ?I70I&D2!(T5$7@*HP!3J*9U1A&"M%6"BBB@H**** "BBB@
MHHHH **** "BBB@ HHHH **** .2\4?\A./_ *XC^;5B5UFLZ7]NO$E\[9B,
M+C;GN??WK._X1[_IZ_\ (?\ ]>OD\;@J\\1.48Z-]T6GH8E%;?\ PCW_ $]?
M^0__ *]'_"/?]/7_ )#_ /KUR_V?B?Y?Q7^8[F)16W_PCW_3U_Y#_P#KT?\
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M5>QQE%=G_P (%_U$_P#R!_\ 94?\(%_U$_\ R!_]E0'U:KV.,HKL_P#A O\
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M7L<9179_\(%_U$__ "!_]E1_P@7_ %$__('_ -E0'U:KV.,HKL_^$"_ZB?\
MY _^RH_X0+_J)_\ D#_[*@/JU7L<9179_P#"!?\ 43_\@?\ V5'_  @7_43_
M /('_P!E0'U:KV.,HKL_^$"_ZB?_ ) _^RH_X0+_ *B?_D#_ .RH#ZM5['&4
M5V?_  @7_43_ /('_P!E1_P@7_43_P#('_V5 ?5JO8XRBNS_ .$"_P"HG_Y
M_P#LJ/\ A O^HG_Y _\ LJ ^K5>QQE%=G_P@7_43_P#('_V5'_"!?]1/_P @
M?_94!]6J]CC*] ^%W_'SJ7^Y'_-JI?\ "!?]1/\ \@?_ &5=1X-\/?V)-=M]
MJ\[S54?ZO;C&?<^M,WPU"I&JFT=;1113/7"BBB@ HHHH Y3XA_\ (J2?]=D_
MG7D5>V^*M,_M?1&M?.\K,BMNV[NGMD5PO_"!?]1/_P @?_94F>7C*,YU+Q1Q
ME%=G_P (%_U$_P#R!_\ 94?\(%_U$_\ R!_]E2.7ZM5['&45V?\ P@7_ %$_
M_('_ -E1_P (%_U$_P#R!_\ 94!]6J]C>^&7_($O/^OG_P!E%=O7.>#]&_L7
M3IX/M'G;Y=^=FW' 'J?2NCJCV,/%QI),****#8**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQGQU_R
M.5__ -L__1:U[-7G_B3PC_:FOW5Y]N\KS-GR>5NQA0.NX>E)G)C82G32CW/-
MZ*[/_A O^HG_ .0/_LJ/^$"_ZB?_ ) _^RI'F?5JO8XRBNS_ .$"_P"HG_Y
M_P#LJ/\ A O^HG_Y _\ LJ ^K5>QQE>S5QG_  @7_43_ /('_P!E7H'V#_IK
-_P".TSKPM&<;W1__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
